Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers

European Journal of Clinical Pharmacology

Volumn 62, Issue 7, 2006, Pages 513-521

  Pedersen, Rasmus Steen ^a   Damkier, Per ^b   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Enantioselective pharmacokinetics; Extensive metabolizers; Poor metabolizers; Tramadol

Indexed keywords

2,3 DIDEHYDROSPARTEINE; 5,6 DIDEHYDROSPARTEINE; CYTOCHROME P450 2D6; DRUG METABOLITE; NORTRAMADOL; O NORTRAMADOL; SPARTEINE; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS; DEMETHYLATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ENANTIOSELECTIVITY; GAS CHROMATOGRAPHY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; VOLUNTEER;

ADULT; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; HUMANS; MALE; STEREOISOMERISM; TRAMADOL;

EID: 33745699160     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0135-x     Document Type: Article

References (42)

1. Frankus E, Friderichs E, Kim SM, Osterloh G (1978) On separation of isomeres, structural elucidation and pharmacological characterization of 1-(m-methoxyphenyl)-2-(dimethylaminomethyl)-cyclohexan-1-ol. Arzneimittelforschung 28:114-121
2. Shipton EA (2000) Tramadol - present and future. Anaesth Intensive Care 28:363-374
3. Wu WN, Mckown LA, Liao S (2002) Metabolism of the analgesic drug ULTRAM (R) (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 32:411-425
4. Lintz W, Erlacin S, Frankus E, Uragg H (1981) Biotransformation of tramadol in man and animal. Arzneimittelforschung 31:1932-1943
5. Subrahmanyam V, Renwick AB, Walters DG, Young PJ, Price RJ, Tonelli AP et al (2001) Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 29:1146-1155
6. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an atypical opioid analgesic. J of Pharmacol Exp Ther 260:275-285
7. Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinetics 43:879-923
8. Gillen C, Haurand M, Kobelt DJ, Wnendt S (2000) Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn-Schmiedebergs Arch Pharmacol 362:116-21. DOI 10.1007/s002100000266
9. Lai J, Ma SW, Porreca F, Raffa RB (1996) Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 316:369-732
10. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL et al (1993) Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J of Pharmacol Exp Ther 267:331-340
11. Bamigbade TA, Davidson C, Langford RM, Stamford JA (1997) Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 79:352-356
12. Halfpenny DM, Callado LF, Hopwood SE, Bamigbade TA, Langford RM, Stamford JA (1999) Effects of tramadol stereoisomers on norepinephrine efflux and uptake in the rat locus coeruleus measured by real time voltammetry. Br J Anaesth 83:909-915
13. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243
14. Halling J, Petersen M, Damkier P, Nielsen F, Grandjean P, Weihe P et al (2005) Polymorphism of Cyp2D6, Cyp2C19, Cyp2C9 and Cyp2C8 in the Faroese population. Eur J Clin Pharmacol 61:491-497. DOI 10.1007/s00228-005-0938-1
15. Paar WD, Poche S, Gerloff J, Dengler HJ (1997) Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 53:235-239
16. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH (1996) The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636-644
17. Pedersen RS, Brosen K, Nielsen F (2003) Enantioselective HPLC method for quantitative determination of tramadol and O-desmethyltramadol in plasma and urine: application to clinical studies. Chromatographia 57:279-285
18. Pedersen RS, Damkier P, Brosen K (2005) Tramadol as a new probe for cytochrome P450 2D6 phenotyping: apopulation study. Clin Pharmacol Ther 77:458-67. DOI 10.1016/j.clpt.2005.01.014
19. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K (2005) Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77:312-323
20. Fliegert F, Kurth B, Gohler K (2005) The effects of tramadol on static and dynamic pupillometry in healthy subjects-the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol 61:257-266. DOI 10.1007/s00228-005-0920-y
21. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A et al (2003) Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105:231-238. DOI 10.1016/S0304-3959(03)00212-4
22. Schellens JHM, Vanderwart HHF, Hoevers JW, Breimer DD (1988) Gas-chromatographic determination of sparteine and 2-Dehydrosparteine and 5-Dehydrosparteine in plasma and urine. J Chromatogr - Biomedical Applications 431:203-209
23. Brosen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57:357-360
24. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome-P450Iid6 gene (Cyp2D6) in poor metabolizers of debrisoquine - study of the functional-significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214
25. Marez D, Legrand M, Sabbagh N, LoGuidice JM, Spire C, Lafitte JJ et al (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202
26. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ (1990) The human Cyp2D locus associated with a common genetic-defect in drug oxidation: a G1934-A base change in intron-3 of a mutant Cyp2D6 allele results in an aberrant-3′ splice recognition site. Am J Hum Genet 47:994-1001
27. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M et al (1990) Identification of the primary gene defect at the cytochrome-P450 Cyp2D locus. Nature 347:773-776
28. Evert B, Griese EU, Eichelbaum M (1994) Cloning and sequencing of a new nonfunctional Cyp2D6 allele - deletion of T-1795 in exon-3 generates a premature stop codon. Pharmacogenetics 4:271-274
29. Daly AK, Leathart JBS, London SJ, Idle JR (1995) An inactive cytochrome-P450 Cyp2D6 allele containing a deletion and a base substitution. Hum Genet 95:337-341
30. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE et al (1994) Identification of a new variant Cyp2D6 allele with a single-base deletion in exon-3 and its association with the poor metabolizer phenotype. Hum Mol Genet 3:923-926
31. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W et al (1991) Identification of a new variant Cyp2D6 allele lacking the codon encoding Lys-281-possible association with the poor metabolizer phenotypee. Pharmacogenetics 1:26-32
32. Broly F, Meyer UA (1993) Debrisoquine oxidation polymorphism - phenotypic consequences of a 3-base-pair deletion in exon 5 of the Cyp2D6 gene. Pharmacogenetics 3:123-130
33. Lintz W, Barth H, Becker R, Frankus E, Schmidt-Bothelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations-2nd communication: drops with ethanol. Arzneimittelforschung 48:436-445
34. Lintz W, Barth H, Osterloh G, Schmidtbothelt E (1986) Bioavailability of enteral tramadol formulations. 1. Capsules. Arzneimittelforschung 36-2:1278-1283
35. Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations, 3rd communication: suppositories. Arzneimittelforschung 48:889-899
36. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH (20061) The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 102:146-150. DOI 10.1213/01.ane.0000189613.613.61910.32
37. Klotz U (2003) Tramadol - the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 53):681-687
38. Bamigbade TA, Langford RM (1998) Tramadol hydrochloride: an overview of current use. Hosp Med 59:373-376
39. Lee CR, Mctavish D, Sorkin EM (1993) Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 46:313-340
40. Paar WD, Frankus P, Dengler HJ (1992) The metabolism of tramadol by human liver-microsomes. Clinical Investigator 70:708-710
41. Liu HC, Wang N, Yu Y, Hou YN (2003) Stereoselectivity in trans-tramadol metabolism and trans-O-demethyltramadol formation in rat liver microsomes. Acta Pharmacol Sin 24:85-90
42. Lintz W, Becker R, Gerloff J, Terlinden R (2000) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations-4th Communication: Drops (without ethanol). Arzneimittelforschung 50:99-108